ICCC vs. AWH, ABIO, VNRX, OCX, CDIO, TRIB, BMRA, TKNO, ACHV, and ICU
Should you be buying ImmuCell stock or one of its competitors? The main competitors of ImmuCell include Aspira Women's Health (AWH), ARCA biopharma (ABIO), VolitionRx (VNRX), OncoCyte (OCX), Cardio Diagnostics (CDIO), Trinity Biotech (TRIB), Biomerica (BMRA), Alpha Teknova (TKNO), Achieve Life Sciences (ACHV), and SeaStar Medical (ICU). These companies are all part of the "medical" sector.
ImmuCell (NASDAQ:ICCC) and Aspira Women's Health (NASDAQ:AWH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends.
In the previous week, ImmuCell had 1 more articles in the media than Aspira Women's Health. MarketBeat recorded 1 mentions for ImmuCell and 0 mentions for Aspira Women's Health. ImmuCell's average media sentiment score of 0.00 equaled Aspira Women's Health'saverage media sentiment score.
ImmuCell has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Aspira Women's Health has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.
ImmuCell has a net margin of -33.05% compared to Aspira Women's Health's net margin of -176.74%. ImmuCell's return on equity of -21.79% beat Aspira Women's Health's return on equity.
ImmuCell received 108 more outperform votes than Aspira Women's Health when rated by MarketBeat users. Likewise, 73.33% of users gave ImmuCell an outperform vote while only 30.95% of users gave Aspira Women's Health an outperform vote.
13.5% of ImmuCell shares are held by institutional investors. Comparatively, 12.2% of Aspira Women's Health shares are held by institutional investors. 6.3% of ImmuCell shares are held by company insiders. Comparatively, 4.3% of Aspira Women's Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Aspira Women's Health has a consensus target price of $4.45, suggesting a potential upside of 27.14%. Given Aspira Women's Health's higher possible upside, analysts plainly believe Aspira Women's Health is more favorable than ImmuCell.
ImmuCell has higher revenue and earnings than Aspira Women's Health. ImmuCell is trading at a lower price-to-earnings ratio than Aspira Women's Health, indicating that it is currently the more affordable of the two stocks.
Summary
ImmuCell beats Aspira Women's Health on 11 of the 16 factors compared between the two stocks.
Get ImmuCell News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuCell Competitors List
Related Companies and Tools
